EMEA-001113-PIP01-10-M06 - paediatric investigation plan
Delamanid
PIPHuman
Otsuka Pharmaceutical Development & Commercialisation Europe GmbH
Tel. +49 6995 5044321
E-mail: paediatric-info@otsuka.de
P/0271/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (Deltyba), (EMEA-001113-PIP01-10-M06)